US Patent

US8895601 — Pyrazolyl quinoxaline kinase inhibitors

Composition of Matter · Assigned to Astex Therapeutics Ltd · Expires 2033-04-12 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects new quinoxaline derivative compounds and their use in treating diseases, such as cancer, and their preparation and pharmaceutical compositions.

USPTO Abstract

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US8895601
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-04-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.